TABLE 1.
Initial Laboratory Results at Our Institution, Echocardiogram Results, Respiratory Support, and Length of Stay
| Reference Range | Critical Illness (n = 5) | Moderate Illness (n = 8) | Mild Illness (n = 20) | P | |
|---|---|---|---|---|---|
|
| |||||
| Median (IQR) initial WBC, k/uL | 4.3–11.0 | 14.2 (11.7–16.0) | 12.3 (9.4–17.9) | 11.7 (10.4–14.5) | 0.703 |
| Median (IQR) initial ANC, /uL | 1540–7920 | 12,260 (11,140–14,070) | 7405 (6250–11,305) | 6710 (5130–9470) | 0.052 |
| Median (IQR) initial ALC, /uL | 970–3960 | 850 (300–910) | 3005 (1710–3510) | 2940 (1605–4725) | 0.005 |
| Median (IQR) initial hemoglobin, g/dL | 11.5–15.5 | 12.4 (11.2–12.5) | 10.6 (10.0–11.5) | 11.3 (10.7–12.6) | 0.254 |
| Median (IQR) initial platelet count, k/uL | 150–400 | 150 (135–155) | 361 (317–461) | 252 (204–492) | 0.005 |
| Median (IQR) initial sodium, mmol/L | 138–145 | 129 (125–129) | 136 (134–137) | 136 (135–140) | 0.002 |
| Median (IQR) initial albumin, g/dL | 3.7–5.6 | 3.8 (3.6–4.0) | 4.4 (3.6–4.4) | 4.3 (3.9–4.6) (n = 18/20) |
0.174 |
| Median (IQR) initial creatinine, mg/dL | 0.1–1.0, age dependent | 0.7 (0.6–1.5) | 0.2 (0.2–0.3) | 0.3 (0.2–0.5) | 0.002 |
| Median (IQR) initial ESR, mm/h | 0–20 | 58 (38–90) (n = 4/5) |
76 (49–88) | 52 (33–90) (n = 16/20) |
0.698 |
| Median (IQR) initial CRP, mg/dL | 0.0–0.9 | 16.8 (14.7–23.5) | 6.7 (3.0–11.4) | 7.2 (4.5–15.1) | 0.090 |
| Median (IQR) initial procalcitonin, ng/mL | 0.00–0.10 | 15.2 (14.2–15.3) (n = 3/5) |
1.4 (1.4–1.4) (n = 1/8) |
12.4 (0.2–24.7) (n = 2/20) |
0.465 |
| Median (IQR) initial BNP, pg/mL | 0.0–100.0 | 664 (562–818) (n = 4/5) |
163 (10–234) (n = 3/8) |
15 (10–25) (n = 4/20) |
0.025 |
| Median (IQR) initial troponin, ng/mL | 0.00–0.30 | 0.48 (0.21–0.99) (n = 4/5) |
(0.01–0.01) (n = 3/8) |
(0.01–0.02) (n = 6/20) |
0.009 |
| Median (IQR) initial D-dimer, ug/mL | 0.00–0.499 | 3.6 (1.8–5.7) (n = 4/5) |
1.9 (1.6–2.2) (n = 2/8) |
0.7 (0.5–0.8) (n = 4/20) |
0.032 |
| Positive SARS-CoV-2 PCR, n/tested (%) | 3/5 (60.0) | 1/7 (14.3) | 1/14 (7.1) | 0.049 | |
| Positive SARS-CoV-2 IgG, n/tested (%) | 2/2 (100) | 0/2 (0) | 0/2 (0) | 0.200 | |
| Positive SARS-CoV-2 PCR OR IgG, n/tested (%) | 4/5 (80.0) | 1/7 (14.3) | 1/14 (7.1) | 0.003 | |
| Abnormal ventricular function on echo, n/tested (%) | 3/5 (60.0) | 0/8 (0) | 0/5 (0) | 0.009 | |
| Coronary artery dilation on echo, n/tested (%) | 2/5 (60.0) | 0/8 (0) | 0/5 (0) | 0.054 | |
| Vasoactive medications administered, n (%) | 3 (60.0) | 0 (0) | 0 (0) | 0.002 | |
| Intravenous immunoglobulin administered, n (%) | 5 (100) | 8 (100) | 0 (0) | <0.001 | |
| Corticosteroids administered, n (%) | 5 (100) | 3 (37.5) | 1 (5.0) | 0.001 | |
| NIPPVadministered, n (%) | 3 (60.0) | 0 (0) | 0 (0) | <0.001 | |
| Intubation, n (%) | 2 (40.0) | 0 (0) | 0 (0) | 0.019 | |
| Median (IQR) hospital length of stay in days | 10 (8–11) | 5 (4–7) | 2 (2–4) | 0.003 | |
Laboratories values reported collected on all patients unless otherwise noted.
ANC indicates absolute neutrophil count; BNP, brain natriuretic peptide; IVIG, intravenous immunoglobulin; NIPPV, noninvasive positive pressure ventilation.